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Transvenous cardiac pacemakers deﬁnitely improve quality of
life and reduce mortality in at-risk patients, but they are associated
with several potential device-related complications. Approximately
10% of patients experience complications related to transvenous
implantation of the pacemaker. These may be attributable to either
the pulse generator (hematoma, skin breakdown, pocket infection)
or venous access and lead implantation (pneumothorax, cardiac
tamponade, lead dislodgement) [1]. Pacemaker leads continue to
be the “Achilles' heel” of the pacing and deﬁbrillation systems. In
the long term, transvenous leads, often considered theweakest link
of the cardiac pacing system, can cause venous obstruction and are
prone to insulation breaks, conductor fractures, and infections
[1e3].
2. Permanent leadless cardiac pacing
Results of the LEADLESS trial
Reddy et al. [4] in a prospective nonrandomized study showed
the safety and feasibility of a novel, completely self-contained
leadless cardiac pacemaker (LCP) in 33 patients. The primary
safety end point was freedom from complications at 90 days. Sec-
ondary performance end points included implant success rate,
implant time, and measures of device performance (pacing/sensing
thresholds and rate-responsive performance). The most common
indication for cardiac pacing was permanent atrial ﬁbrillation with
atrioventricular block. The implant success rate was 97%. Five pa-
tients (15%) required the use of >1 leadless cardiac pacemaker
during the procedure. One patient developed right ventricular
perforation and cardiac tamponade during the implant procedure,E-mail address: arungopi@gmail.com.
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complication-free rate was 94% (31/33). After 3 months of follow-
up, the measures of pacing performance (sensing, impedance,
and pacing threshold) either improved or were stable within the
accepted range [4].2.2. Chronic performance of a leadless cardiac pacemaker
Year follow-up of the LEADLESS trial
Knops and colleagues [5], retrospectively assessed
intermediate-term follow-up data for 31 of 33 patients from the
LEADLESS trial cohort who had an indication for single-chamber
pacing. Between 3 and 12months of follow-up, there were no
pacemaker-related adverse events reported. The pacing perfor-
mance results at 6- and 12-month follow-up were, respectively, as
follows:mean pacing threshold(at a 0.4-mspulsewidth), 0.40 Vand
0.43 V; R-wave amplitude 10.6 mV and 10.3 mV; and impedance
625 U and 627 U. At the 12-month follow-up in 61%of the patients
(n 19 of 31), the rate response sensor was activated, and an
adequate rate response was observed in all patients. This study
demonstrates very stable performance and reassuring safety results
during intermediate-term follow-up of leadless pacemaker.2.3. Percutaneous implantation of an entirely intracardiac leadless
pacemaker
LEADLESS II study [6] was a prospective, nonrandomized,
multicenter trial which examined the clinical safety and efﬁcacy of
the Nanostim leadless cardiac pacemaker in patients who require
permanent ventricular pacing. Reddy et al. [6] reported the interim
analysis, which includes the primary analysis of efﬁcacy and safety
in the initial 300 patients who were followed for 6 months (the
primary cohort) and outcomes for all 526 patients who were
enrolled as of June 2015 (the total cohort). The primary efﬁcacy end
point was both an acceptable pacing threshold (2.0 V at 0.4 msec)
and an acceptable sensing amplitude (R wave 5.0 mV, or a value
equal to or greater than the value at implantation) through 6
months. The primary safety end point was freedom from device-
related serious adverse events through 6 months. The rates of the
efﬁcacy end point and safety end point were compared with per-
formance goals (based on historical data) of 85% and 86%, respec-
tively. The leadless pacemaker was successfully implanted in 504 ofElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Comparison of leadless pacemakers.
Device Size
(cm3)
Means of
ﬁxation
No. of
patients
Successful
implantation (%)
Major
complication (%)
Perforation or
effusion (%)
Device
dislodgement
Adequate pacing parameters at 6
months (%)
Nanostim 1.0 Helical wire
screw
526 95.8 6.5 1.5 1.1 90
Micra 0.8 Tines 725 99.2 4 1.6 0 98.3
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primary efﬁcacy end point was met in 270 of the 300 patients in
the primary cohort (90.0%; 95% conﬁdence interval [CI], 86.0 to
93.2, p¼ 0.007), and the primary safety end point wasmet in 280 of
the 300 patients (93.3%; 95% CI, 89.9 to 95.9; P < 0.001). The mean
pacing threshold and sensing values at 6 months were similar to
those observed with conventional transvenous leads [7] and these
values were stable over time. At 6 months, device-related serious
adverse events were observed in 6.7% (approximately 1 in 15) of the
patients; events included device dislodgement with percutaneous
retrieval (in 1.7%), cardiac perforation (in 1.3%), and pacing-
threshold elevation requiring percutaneous retrieval and device
replacement (in 1.3%).
2.4. A leadless intracardiac transcatheter pacing system
Micra Transcatheter Pacing Study [8] is a prospective, non-
randomized, single-study-group, multisite, international clinical
study to evaluate the safety and efﬁcacy of the Micra Pacemaker
System (Medtronic). The analysis of the primary end points began
when 300 patients reached 6 months of follow-up. The primary
safety end point was freedom from system-related or procedure
related major complications. The primary efﬁcacy end point was
the percentage of patients with low and stable pacing capture
thresholds at 6months (2.0 V at a pulsewidth of 0.24msec and an
increase of 1.5 V from the time of implantation). They also did a
post hoc analysis in which the rates of major complications were
compared with those in a control cohort of 2667 patients with
transvenous pacemakers from six previously published studies. The
device was successfully implanted in 719 of 725 patients (99.2%).
The Kaplane Meier estimate of the rate of the primary safety end
point was 96.0% (95% conﬁdence interval [CI], 93.9 to 97.3;
P < 0.001 for the comparison with the safety performance goal of
83%); there were 28 major complications in 25 of 725 patients, and
no dislodgements. The rate of the primary efﬁcacy end point was
98.3% (95% CI, 96.1 to 99.5; p < 0.001 for the comparison with the
efﬁcacy performance goal of 80%) among 292 of 297 patients with
paired 6-month data. Although there were 28 major complications
in 25 patients, patients with transcatheter pacemakers had signif-
icantly fewer major complications than did the control patients
(hazard ratio, 0.49; 95% CI, 0.33 to 0.75; p¼ 0.001). In this historical
comparison study, the transcatheter pacemaker met the pre-
speciﬁed safety and efﬁcacy goals; it had a safety proﬁle similar to
that of a transvenous systemwhile providing low and stable pacing
thresholds [8].
An editorial [9] compared (Table 1) these two nonrandomized,industry-sponsored studies of leadless pacemakers(the Nanostim
device from St. Jude Medical and Micra device from Medtronic).
These studies demonstrate that leadless pacing is feasible and
relatively safe, at least in the short term. Whether the long-term
results will show that these devices remain safe and effective
over time and that these leadless devices are as durable as trans-
venous pacemakers remains to be seen. To date, these newer de-
vices can be used only for single-chamber ventricular pacing, a
procedure generally reserved for patients with atrial ﬁbrillation
and bradycardia or in patients thought to need infrequent pacing.
These leadless pacemakers will have limited usefulness in the
treatment of the majority of pacemaker recipients, including pa-
tients with sinus-node dysfunction or heart block, and they will
have no role in the treatment of patients with heart failure who
need left-ventricular resynchronization to improve cardiac output.
In spite of these concerns, these studies have encouraging short-
term results that show the promise of leadless pacing; they are
likely to generate substantial interest in leadless pacing and deﬁ-
brillation technology. Importantly, the results of these studies
suggest the potential value of the next generation of leadless de-
vices, which will include atrial-based systems and left ventricular
resynchronization systems that are more widely applicable [9].References
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